The future of COVID-19 vaccines needs more data

On Thursday, the FDA’s Vaccines and Related Biological Products Advisory Committee (or VRBPAC) met to discuss the future of COVID-19 vaccines. While the committee readily agreed that our current, Omicron-specific shots are working well and should be used more broadly, it had a hard time answering other questions about future vaccine regimens—largely due to a lack of good data.

Read More

New Long COVID studies demonstrate danger of breakthrough cases

Two new studies on Long COVID, published this week, provide an important reminder of the continued dangers this condition poses to people infected with the coronavirus—even after vaccination. Neither study provides wholly new information, but both are more comprehensive than many other U.S. papers on this condition as they’re based on large databases of electronic health records.

Read More

The US still doesn’t have the data we need to make informed decisions on booster shots

Last fall, I wrote that the U.S. did not have the data we needed to make informed decisions about booster shots. Several months later, we still don’t have the data we need, as questions about a potential BA.2 wave and other future variants abound. Discussions at a recent FDA advisory committee meeting made these data gaps clear.

Read More